Login to Your Account

Clinic Roundup

Wednesday, October 30, 2013
• Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., provided an update on the status of its Phase III trial with lead candidate Firdapse (amifampridine phosphase) for the treatment of Lambert-Eaton myasthenic syndrome.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription